1. Home
  2. APTO vs CDT Comparison

APTO vs CDT Comparison

Compare APTO & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APTO
  • CDT
  • Stock Information
  • Founded
  • APTO 1986
  • CDT 2019
  • Country
  • APTO Canada
  • CDT United States
  • Employees
  • APTO N/A
  • CDT N/A
  • Industry
  • APTO Biotechnology: Biological Products (No Diagnostic Substances)
  • CDT Biotechnology: Pharmaceutical Preparations
  • Sector
  • APTO Health Care
  • CDT Health Care
  • Exchange
  • APTO Nasdaq
  • CDT Nasdaq
  • Market Cap
  • APTO 11.5M
  • CDT 10.2M
  • IPO Year
  • APTO N/A
  • CDT N/A
  • Fundamental
  • Price
  • APTO $0.18
  • CDT $0.07
  • Analyst Decision
  • APTO Strong Buy
  • CDT
  • Analyst Count
  • APTO 3
  • CDT 0
  • Target Price
  • APTO $4.33
  • CDT N/A
  • AVG Volume (30 Days)
  • APTO 1.4M
  • CDT 43.4M
  • Earning Date
  • APTO 11-08-2024
  • CDT 02-14-2025
  • Dividend Yield
  • APTO N/A
  • CDT N/A
  • EPS Growth
  • APTO N/A
  • CDT N/A
  • EPS
  • APTO N/A
  • CDT N/A
  • Revenue
  • APTO N/A
  • CDT N/A
  • Revenue This Year
  • APTO N/A
  • CDT N/A
  • Revenue Next Year
  • APTO N/A
  • CDT N/A
  • P/E Ratio
  • APTO N/A
  • CDT N/A
  • Revenue Growth
  • APTO N/A
  • CDT N/A
  • 52 Week Low
  • APTO $0.13
  • CDT $0.07
  • 52 Week High
  • APTO $2.68
  • CDT $6.73
  • Technical
  • Relative Strength Index (RSI)
  • APTO 29.73
  • CDT 37.75
  • Support Level
  • APTO $0.18
  • CDT $0.08
  • Resistance Level
  • APTO $0.22
  • CDT $0.09
  • Average True Range (ATR)
  • APTO 0.01
  • CDT 0.01
  • MACD
  • APTO 0.01
  • CDT -0.00
  • Stochastic Oscillator
  • APTO 22.50
  • CDT 7.61

About APTO Aptose Biosciences Inc.

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

About CDT Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Share on Social Networks: